

SAHPRA Head Office Building A Loftus Park 2<sup>nd</sup> Floor Kirkness Road Arcadia 0083

**MAY 2022** 

## COMMUNICATION TO STAKEHOLDERS ON PAYMENT OF ANNUAL RETENTION FEES FOR REGISTERED PRODUCTS

## INTRODUCTION

The Medicines and Related Substances Act, 1965 (Act 101 of 1965) as amended, ("the Medicines Act") makes provision for the payment of retention fees to the Regulatory Authority in respect of medicines, medical devices and IVDs registered and site licences issued.

Further to the above, Regulation GNR 784 as published in the Government Gazette 42474 dated 22 DECEMBER 2020 read in conjunction with the Medicines Act, states that : *The following fees shall be paid to the Chief Executive Officer:* 

Human medicines - Schedule 1 (b) (iv): "Annually, in respect of the retention of the registration of a medicine, the registration of which has been approved by the Authority in terms of section 15(3): **R5 000**: Provided that this provision shall come into effect one year after the date on which the registration of said medicine was approved by the Authority in terms of section 15(3); Provided further that the said fees payable during a particular **calendar year** shall be payable on or before the last working day of **June of that year**, failing which the registration may be cancelled in terms of section 16(4)."

Veterinary medicines - Schedule 2 (b) (iv): "Annually, in respect of the retention of the registration of a medicine, the registration of which has been approved by the Authority in terms of Section 15(3): **R2 300**: Provided that this provision shall come into effect one year after the date on which the registration of the

Chairperson: Prof Helen Rees • Vice-Chairperson: Dr Obakeng Khaole • Prof Joyce Tsoka-Gwegweni Prof Patrick Demana • Dr Xolani Khayelihle Ngobese • Adv Hasina Cassim • Ms Ditaba Lucy Maraka Mr Itani Elias Mashau • Ms Lerato Mothae • Mr Norman Baloyi • Dr Afred Kgasi • Prof Johanna Meyer • Ms Mandisa Skhosana • Prof Yahya Choonara • Dr Zinhle Makatini CEO: Dr Boitumelo Semete-Makokotlela said medicine was approved by the Authority in terms of Section 15(3); Provided further that the said fees payable during a particular **calendar year** shall be payable on or before the last working day of **June that year**, failing which the registration may be cancelled in terms of Section 16(4)."

Schedule 6 (c): "Annually, in respect of the retention of a licence issued in terms of section 22C(1)(b) of the Act: **R4 200**, and this fee is payable on or before the last working day of **June that year**, failing which registration may be cancelled"

In terms of the above Regulations the annual retention fees therefore become due in a particular calendar year (January – December) will be payable in June of the year it becomes due.

Furthermore, the above practice has been confirmed to be reasonable and it has been consistently applied.

## NOTIFICATION OF ANNUAL RETENTION FEE PAYMENT

SAHPRA will issue the notification for payment of Annual retention fees in June 2022. The notification will include guidance on the following information:

- Method of payment
- SAHPRA bank details
- References to be used
- Proof of payment
- Payment communication details

## PROCESS FOR PAYMENT OF ANNUAL RETENTION FEE

- An applicant specific product line listing and the corresponding invoice will be communicated to the applicant before the 15<sup>th</sup> of June 2022.
- These retention fees are payable by no later than 30 June of the calendar year, failing which the registration cancellation process will commence.



CHIEF EXECUTIVE OFFICER